Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer”

52 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 52 results

Testing effectiveness (Phase 2)Ended earlyNCT01912963
What this trial is testing

Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast Cancer
Dana-Farber Cancer Institute 32
Large-scale testing (Phase 3)UnknownNCT04924699
What this trial is testing

MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced Breast CancerMetastatic Breast Cancer
Shanghai Miracogen Inc. 350
Testing effectiveness (Phase 2)UnknownNCT05334810
What this trial is testing

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

Who this might be right for
HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 191
Testing effectiveness (Phase 2)Active Not RecruitingNCT02849496
What this trial is testing

Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Unresectable Breast Carcinoma+1 more
National Cancer Institute (NCI) 81
Testing effectiveness (Phase 2)WithdrawnNCT06105008
What this trial is testing

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
RemeGen Co., Ltd.
Testing effectiveness (Phase 2)Looking for participantsNCT07002177
What this trial is testing

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Who this might be right for
Metastatic Breast CancerBreast Cancer Stage IBreast Cancer Stage II+2 more
Forward Pharmaceuticals Co., Ltd. 196
Not applicableUnknownNCT04202328
What this trial is testing

T-DM1 in HER2-positive Metastatic/Relapsed Breast Cancer

Who this might be right for
Breast Cancer
Samsung Medical Center 1,000
Testing effectiveness (Phase 2)Looking for participantsNCT07182721
What this trial is testing

SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment

Who this might be right for
HER2-positive, Unresectable, Locally Advanced or Metastatic Breast CancerSKB264Inetetamab
Fudan University 48
Testing effectiveness (Phase 2)Looking for participantsNCT06686394
What this trial is testing

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Who this might be right for
Breast NeoplasmsBreast Cancer
Merck Sharp & Dohme LLC 81
Large-scale testing (Phase 3)Active Not RecruitingNCT06316531
What this trial is testing

A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 274
Large-scale testing (Phase 3)Looking for participantsNCT07071337
What this trial is testing

SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy

Who this might be right for
Metastatic Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 430
Not applicableStudy completedNCT02595762
What this trial is testing

Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast Cancer
Hoffmann-La Roche 110
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06224673
What this trial is testing

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
HER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast Cancer+1 more
Laura Huppert, MD, BA 36
Large-scale testing (Phase 3)UnknownNCT05755048
What this trial is testing

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 314
Testing effectiveness (Phase 2)Ended earlyNCT05583110
What this trial is testing

Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
HER2-positive Metastatic Breast CancerLocally Advanced HER2 Positive Breast Carcinoma
Spanish Breast Cancer Research Group 13
Testing effectiveness (Phase 2)Looking for participantsNCT06428396
What this trial is testing

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Who this might be right for
Metastatic Breast Cancer
Merck Sharp & Dohme LLC 120
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07116824
What this trial is testing

HB1801 Combined Treatment of HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 80
Large-scale testing (Phase 3)Looking for participantsNCT04862663
What this trial is testing

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

Who this might be right for
Locally Advanced (Inoperable) or Metastatic Breast Cancer
AstraZeneca 895
Large-scale testing (Phase 3)Study completedNCT04732598
What this trial is testing

A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer

Who this might be right for
Breast Cancer
Japanese Foundation for Cancer Research 281
Early research (Phase 1)Study completedNCT03767335
What this trial is testing

MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer

Who this might be right for
Advanced or Metastatic Breast Cancer
Menarini Group 62
Load More Results